Welcome to our dedicated page for Adverum Biotech news (Ticker: ADVM), a resource for investors and traders seeking the latest updates and insights on Adverum Biotech stock.
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) is a clinical-stage gene therapy pioneer developing innovative treatments for ocular and rare diseases through its proprietary intravitreal platform. This resource provides investors and medical professionals with essential updates on the company's clinical trials, regulatory milestones, and strategic initiatives.
Access real-time information about ADVM's AAV-based therapies designed to reduce treatment burdens in conditions like wet AMD. The page aggregates official press releases, partnership announcements, and trial result disclosures - critical data for evaluating the company's progress in advancing durable single-dose therapies.
Key content includes updates on lead candidates like the wet AMD gene therapy program, manufacturing developments, and peer-reviewed research publications. Track progress across therapeutic areas including ophthalmology and rare genetic disorders through verified company communications.
Bookmark this page for streamlined access to ADVM's latest scientific advancements and corporate updates. Check regularly for new developments in their mission to transform chronic disease management through groundbreaking gene therapy approaches.
Adverum Biotechnologies (Nasdaq: ADVM) has appointed Christopher J. DeRespino as its new Chief Business Officer, effective immediately. DeRespino brings over 15 years of pharmaceutical experience, having previously served in leadership roles at Amgen and Onyx Pharmaceuticals. His focus will be on advancing corporate strategy and global business development, especially concerning ADVM-022, a gene therapy aimed at treating wet AMD. The company has also granted him stock options for 425,000 shares, effective upon his employment.
Adverum Biotechnologies (Nasdaq: ADVM) announced data from Cohorts 1-4 of the OPTIC Phase 1 clinical trial for ADVM-022, a gene therapy targeting wet age-related macular degeneration (AMD). The presentation will take place on February 13, 2021, at 9:30 am ET, showcasing the therapy's potential benefits for patients requiring frequent anti-VEGF treatments. ADVM-022 represents a significant advancement in treating AMD and diabetic macular edema, aiming for a one-time intravitreal injection solution.
Adverum Biotechnologies (Nasdaq: ADVM) announced the completion of patient enrollment in the INFINITY Phase 2 trial for ADVM-022, targeting diabetic macular edema (DME). Data is anticipated in the second half of 2021. A pivotal trial for ADVM-022 in wet age-related macular degeneration (AMD) is planned for mid-2021 after regulatory discussions. The company is also developing a new GMP manufacturing facility in North Carolina, expected to be production-ready by the end of 2023, enhancing its capacity to support clinical and commercial needs.
Adverum Biotechnologies (ADVM) is set to invest over $80 million in a new 174,000-square-foot Good Manufacturing Practices facility in Durham, NC, aimed at producing ADVM-022 for wet AMD and DME. The facility will include multiple production suites with a total capacity of 4000L and is expected to create over 200 jobs. Adverum will also receive up to $9 million in state and local incentives to support this initiative. The facility is anticipated to be production-ready by the end of 2023, underpinning Adverum's commercialization strategy for its gene therapy products.
Adverum Biotechnologies (Nasdaq: ADVM), a clinical-stage gene therapy company focusing on ocular and rare diseases, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 10:50 a.m. ET. The presentation will highlight the company’s innovative gene therapy candidate, ADVM-022, aimed at treating wet age-related macular degeneration and diabetic macular edema. A live webcast of the event will be available on Adverum's website, and an archived version will be accessible for 30 days following the presentation.
Adverum Biotechnologies (Nasdaq: ADVM) announced the appointment of Dawn Svoronos to its Board of Directors. Svoronos, with 30 years in the biopharmaceutical sector, most notably at Merck, is expected to guide the commercialization of the company's gene therapy candidate ADVM-022. This therapy aims to treat ocular diseases, particularly wet AMD and diabetic macular edema. The company is preparing for a pivotal Phase 2b trial in mid-2021, highlighting its commitment to addressing significant medical needs.
Adverum Biotechnologies (Nasdaq: ADVM) announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. The company focuses on addressing unmet medical needs in ocular and rare diseases. A video webcast of their presentation will be available on demand starting at 10:00 am ET today and can be accessed for 30 days on their website. Adverum is advancing its gene therapy candidate, ADVM-022, aimed at treating wet age-related macular degeneration and diabetic macular edema.
Adverum Biotechnologies announced positive interim results from the OPTIC Phase 1 trial of ADVM-022, a gene therapy for wet age-related macular degeneration (AMD). The therapy showed a substantial reduction in the need for anti-VEGF injections, with a 99% reduction in the high-dose group and 85% in the low-dose group. Patients displayed sustained efficacy and safety, with most remaining anti-VEGF injection-free. The FDA has lifted the partial clinical hold, allowing plans for pivotal trials to progress, aiming for initiation in mid-2021.
Adverum Biotechnologies reported significant progress in its clinical programs for ADVM-022 targeting wet AMD and DME. The FDA has removed a partial clinical hold, allowing the company to prepare for a pivotal trial in mid-2021. Financial results for Q3 show cash reserves of $454.5 million, bolstered by a $203.4 million public offering. However, the company reported a net loss of $27.8 million for the quarter, up from $16.1 million last year. Adverum's increased R&D expenses are attributed to growth in personnel and production costs.
Adverum Biotechnologies (Nasdaq: ADVM) announced the upcoming presentation of clinical data from its OPTIC Phase 1 trial, focusing on its ADVM-022 gene therapy for wet age-related macular degeneration (AMD). Dr. Carl Regillo will present this data on November 13, 2020, during the Retina Subspecialty Day at the AAO 2020 Virtual Meeting. A webcast featuring key opinion leaders discussing the new data will follow on November 14, 2020. The company plans to report its third-quarter financial results after the market closes on November 5, 2020.
FAQ
What is the current stock price of Adverum Biotech (ADVM)?
What is the market cap of Adverum Biotech (ADVM)?
